Trial design-OV26

ENGOT-OV26/PRIMA

Clinical Trial Study: OV26

A phase 3, randomized, double-blind, placebo-controlled, multicenter study of Niraparib maintenance treatment in patients with advanced ovarian cancer following response on front-line platinum-based chemotherapy.

Study design